New Antimicrobial Agents in Respiratory Medicine

Moon-Hyun Chung

doi:10.4046/trd.2006.60.1.5

Journal List > Tuberc Respir Dis > v.60(1) > 1000945

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Chung: New Antimicrobial Agents in Respiratory Medicine

Review

Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2006; 60(1): 5-20.

Published online: 31 January 2006

DOI: https://doi.org/10.4046/trd.2006.60.1.5

New Antimicrobial Agents in Respiratory Medicine

Moon-Hyun Chung, M.D.

Department of Internal Medicine, Inha University School of Medicine, Incheon, Repubic of Korea.

Address for correspondence: Moon-Hyun Chung, M.D., Department of Internal Medicine, Inha University School of Medicine, Incheon, Repubic of Korea. Phone: 82-32-890-2202, Fax: 82-32-890-2201, mhchungid@paran.com

Figures and Tables

Figure 1

Linezolid.

Figure 2

Ramoplanin.

Figure 3

Chemical structure of tigecycline and tetracycline.

Figure 4

Chemical structures of gatifloxacin, gemifloxacin, and moxifloxacin.

Figure 5

Telithromycin (ketolide).

Figure 6

Chemical structure of ertapenem.

Figure 7

Voriconazole.

Figure 8

Structure of caspofungin, micafungin, and anidulafungin.

Table 1

Pharmacokinetic properties of certain newer fluoroquinolones

Table 2

In vitro (MIC90) activities of macrolide-ketolide antibiotics

Table 3

Pharmacokinetics of macrolide antibiotics

Table 4

Comparison of the carbapenems

Table 9

Pharmacokinetic characteristics of caspofungin

References

1. Delgado G Jr, Neuhauser MM, Bearden DT, Danziger LH. Quinupristin-dalfopristin: an overview. Pharmacotherapy. 2000. 20:1469–1485.

2. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003. 138:135–142.

3. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother. 2005. 55:283–288.

4. Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH, et al. Emergence of daptomycin resistance in enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005. 49:1664–1665.

5. Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother. 2003. 51:Suppl 3. iii31–iii35.

6. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005. 55:Suppl 2. ii15–ii20.

7. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis. 2004. 49:201–209.

8. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther. 2004. 26:704–714.

9. Roos K, Tellier G, Baz M, Leroy B, Rangaraju M. Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J Infect. 2005. 50:210–220.

10. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002. 96:862–871.

11. Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriologic efficacy of the ketolide telithromycin. J Antimicrob Chemother. 2003. 51:947–955.

12. Perry CM, Ibbotson T. Biapenem. Drugs. 2002. 62:2221–2234.

13. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother. 2003. 52:538–542.

14. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care. 2005. 9:R53–R59.

15. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/ pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis. 2002. 21:212–214.

16. Benifla M, Zucker C, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother. 2004. 54:290–292.

17. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003. 36:630–637.

18. Denning DW. Echinocandin antifungal drugs. Lancet. 2003. 362:1142–1151.

19. Mora-Durik J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002. 347:2020–2029.

20. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventinal antifungal therapy. Clin Infect Dis. 2004. 39:1563–1571.

21. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005. 353:1363–1373.

TOOLS

Similar articles